Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair

In the study, participants will be asked to complete the following:

• Provide basic personal information (including date of birth, gender, race and ethnicity)
• Provide their medical/ surgical history and perform a medical exam (including but not limited to symptom-directed physical exam, skin type, vital signs, height, weight, laboratory assessments and pregnancy test collection)
• Follow study rules such as avoiding certain medications and treatments
• Provide information on any medications, treatments or reactions that started after the study began
• Apply serum and take gummy treatment daily, including completing a treatment diary
• Allow clinical assessments and documentation of the treatment, such as photography, hair density measurements, any reactions or side effects

To qualify for this trial, participants must:

• be a female adult between 28 to 65 years of age
• have consistent self-perceived thinning hair.
• give voluntary written consent
• be willing to follow study instructions and complete study requirements, including maintaining current diet and hair care routine, not using non-approved lotions and creams on the treatments areas
• allow photographs of the front and top area of the scalp
• not be pregnant or breast feeding before and during the study and agree to use acceptable forms of birth control
• confirm they are not sensitive to any of the study treatment ingredients

A relatively small area will be shaved off-center and top of the scalp for a dot-tattoo placement and this marked area will be used for clinical assessments throughout the study.

All photographs of the treatment area collected during the study will be used as study data.

All participants have the right to refuse further participation in the study at any time.

Inclusion criteria

• Female adults between 28-65 years of age with consistent self-perceived thinning hair.
• Ludwig Scale I or II (mild to moderate thinning hair loss), assessed clinically.
• Fitzpatrick Skin Types I to VI.
• Agree to maintain their current diet, medications, exercise routines, hair shampooing, and color treatment frequency for the duration of the study.
• Ability and willingness to comply with the study protocol including regular visits and product application.
• Written informed consent obtained, including written consent to allow photographs to be used as part of the study data and documentation.
• For females of childbearing potential, a negative pregnancy test at screening and commitment to effective contraception throughout the study (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy) to avoid pregnancy-related hormonal changes affecting hair density.

Exclusion criteria

• Pregnant or lactating or planning to become pregnant.
• Changes in hormonal therapy within 6 months prior to enrollment and throughout the study.
• Use of other medical hair loss treatments (e.g., Minoxidil, Dutasteride, Finasteride, laser or light therapy) within 3 months prior to study start and throughout the study.
• Micro-needling, PRP, or any other physical treatment modality on the scalp (within 6 months prior to study start and throughout the study).
• Use of GLP-1 inhibitors (e.g., Semaglutide) within 6 months prior to study start and throughout the study.
• Known uncontrolled health conditions (e.g., thyroid disease, anemia) that could confound study outcomes.
• Known sensitivity to any of the ingredients in the study medication.
• In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.
• Subject has any conditions, findings in history, physical exam or laboratory assessments, which in the opinion of the investigator, would exclude the subject from continuing in this study.
• Treatment with an experimental drug, biologic or device within 12 weeks of the screening visit.